The company’s partner Kelun-Biotech reported positive late-stage trial results for a Keytruda combination treatment in lung ...
Shares of Merck & Co. (MRK) rose 5% on Friday after the pharmaceutical giant reported positive developments across multiple ...
Merck (MRK) shares rose nearly 5% in early trade on Friday after the company said a European medicines committee issued a ...
The trial assesses Precem-TcT efficacy and safety alone or with bevacizumab in mCRC patients after previous therapies.
May 21 () - Moderna and Merck's combination therapy for skin cancer helped reduce risk of cancer spreading to another part ...
A type of targeted chemotherapy developed by China-based Kelun-Biotech and licensed to Merck cut the risk of tumor ...
Merck KGaA, Darmstadt, Germany, Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in ...
Biotech’s antibody-drug conjugate significantly improved progression-free and overall survival in a pivotal endometrial ...
(Reuters) -Merck said on Wednesday it will acquire UK-based Verona Pharma for about $10 billion, gaining a promising respiratory treatment as it faces pressure to diversify beyond its blockbuster ...
Merck narrowed its 2026 sales guidance and hiked its adjusted profit outlook.
Merck KGaA made its largest acquisition in a decade in April 2025 when it snapped up Connecticut rare disease specialist ...
Merck said on Monday its experimental drug met the main goals of a late-stage trial in patients with a cancer of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results